Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation
This study found that PSMA-PET may be associated with improved disease detection but may not be cost-effective due to high treatment costs offsetting moderate improvements in QALYs. Further research is needed to identify patient subsets and clinical scenarios in which molecular imaging provides the greatest value.
Authors
- Maximilian Rabil (ORCID: https://orcid.org/0000-0002-2314-0802)
- Lawrence Saperstein
- Umar Ghaffar (ORCID: https://orcid.org/0000-0001-6789-8052)
- R. Jeffrey Karnes (ORCID: https://orcid.org/0000-0003-2339-5925)
- Natalia Kunst (ORCID: https://orcid.org/0000-0002-2409-4246)
- Cary P. Gross (ORCID: https://orcid.org/0000-0002-4974-935X)
- Preston C. Sprenkle (ORCID: https://orcid.org/0000-0003-0502-9294)
- Isaac Yi Kim (ORCID: https://orcid.org/0000-0001-7167-8853)
- Shi‐Yi Wang (ORCID: https://orcid.org/0000-0002-3294-5784)
- Xiaomei Ma (ORCID: https://orcid.org/0000-0001-8156-8404)
- Michael S. Leapman
- Jessica B. Long
Institutions
- Mayo Clinic (US)
- Yale Cancer Center (US)
- Yale University (US)
- University of York (GB)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.39250
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- AstraZeneca
- Yale University
- National Comprehensive Cancer Network
- National Institutes of Health
- National Cancer Institute